Summary & Overview
HCPCS G9440: P2Y Inhibitor Not Prescribed at Discharge
HCPCS Level II code G9440 documents occurrences when a P2Y receptor inhibitor is not prescribed at hospital discharge for a patient who may otherwise be eligible. This measure is clinically significant because timely initiation of antiplatelet therapy after acute coronary syndromes or percutaneous coronary intervention can affect short-term and long-term outcomes; capturing absence of prescription at discharge supports quality monitoring, safety audits, and care-transition reviews nationwide. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, how it is used in documentation and quality measurement, the payer landscape relevant to its reporting, and where it fits in discharge medication reconciliation processes. The publication summarizes national benchmarks and reporting considerations, summarizes recent policy updates affecting discharge medication measures, and provides clinical context for why capture of omitted P2Y inhibitor prescriptions matters for transitions of care and downstream medication management. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code G9440 indicates P2Y inhibitor not prescribed at discharge. This code documents instances in which a patient eligible for a P2Y receptor inhibitor following an indicated event did not receive a prescription at hospital discharge.
-
Service type: Medication management / discharge medication reconciliation
-
Typical site of service: Inpatient hospital setting (discharge process)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized after an acute coronary syndrome (ACS), such as ST-elevation myocardial infarction (STEMI) or non‑ST elevation myocardial infarction (NSTEMI), or following percutaneous coronary intervention (PCI) with stent placement. During inpatient discharge reconciliation, the treating team documents that a P2Y12 inhibitor (for example clopidogrel, prasugrel, or ticagrelor) was not prescribed at discharge. The clinical workflow includes medication reconciliation by the hospitalist or cardiology team, review by pharmacy for contraindications (active bleeding, allergy, severe hepatic dysfunction, planned surgery), and documentation of the reason for omission in the discharge summary. Nursing staff and case management coordinate outpatient follow‑up and patient education for antiplatelet therapy as appropriate. The code G9440 is used to indicate that a P2Y12 inhibitor was not prescribed at discharge in the context of quality reporting and billing documentation for post‑ACS/PCI care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit on the discharge day is distinct from other services related to the hospitalization and must be reported separately. |